2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide
• 英文别名: PCM-0102376；3-(2-Chloroacetyl)-1-(2-fluorophenyl)urea；2-chloro-N-[(2-fluorophenyl)carbamoyl]acetamide
• 化学式: C₉H₈ClFN₂O₂
• mdl: MFCD06358628
• 分子量: 230.626
• InChiKey: PIHDYGGFNFGFRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide 在 sodium acetate 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(2-fluorophenyl)-1-methyl-1-[2-(3-methylquinoxalin-2-ylsulfanyl)acetyl]urea
  参考文献：
  名称：

  Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

  摘要：

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.06.053
• 作为产物：
  描述：

  2-氟苯胺 、 氯乙酰异氰酸酯 以 二氯甲烷 为溶剂， 生成 2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide
  参考文献：
  名称：

  Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

  摘要：

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.06.053

文献信息

• 신규 N-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물
  申请人：Korea University Research and Business Foundation 고려대학교 산학협력단(220040170680) BRN ▼209-82-08298

  公开号：KR101691954B1

  公开（公告）日：2017-01-02

  본 발명은 신규 N-아실유레아 유도체 및 이의 심혈관질환의 치료 또는 예방 용도에 관한 것으로, 더욱 자세하게는 신규 N-아실유레아 유도체, 상기 N-acylurea 유도체를 유효성분으로 함유하는 심혈관질환의 예방 또는 치료용 약학적 조성물 및 N-아실유레아 유도체의 제조방법에 관한 것으로, 본 발명에 따른 N-acylurea 유도체는 세포내 기질 (intracellular matrix)의 탈린 작용을 억제하여 혈소판 응집을 저해할 수 있으므로 심혈관질환의 예방 또는 치료에 유용하게 사용할 수 있다.

  该专利涉及新型N-酰基脲衍生物及其在心血管疾病的治疗或预防中的用途，更具体地说，涉及新型N-酰基脲衍生物，包含上述N-酰基脲衍生物作为有效成分的用于心血管疾病预防或治疗的药学组合物，以及关于N-酰基脲衍生物的制备方法，根据本发明的N-酰基脲衍生物能够抑制细胞内基质的塔林作用，从而可以有效用于心血管疾病的预防或治疗。
• Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress
  作者：H. Marie Loughran、Ziying Han、Jay E. Wrobel、Sarah E. Decker、Gordon Ruthel、Bruce D. Freedman、Ronald N. Harty、Allen B. Reitz

  DOI：10.1016/j.bmcl.2016.06.053

  日期：2016.8

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.